Indeed, the targeting of RBD has been highlighted in a number of recent works ranging for the use of soluble human ACE2, i.e., not anchored to the cellular membrane, able to prevent virus infection in organoids [6], engineered variants of soluble human ACE2 showing higher affinity to RBD to be used as decoys [7], computationally designed mini-proteins to mimic ACE2 with outstanding pico-molar binding affinities [8], and a range of monoclonal antibodies [9,10], nanobodies [11,12], as well as aptamers [13,14] that target RBD. Here, ACE2 is linked to viral infectious disease.